Welcome to the Cerba Research Oncology Blog — where science meets practical execution. Our global oncology experts translate complex science into clear, actionable insight, sharing how advanced laboratory techniques are shaping today’s clinical trials. From flow cytometry and IHC to NGS and multiplexed strategies, we explore how integrated biomarker solutions accelerate smarter decision‑making in immuno-oncology.

Why Read Our Blog
This blog brings together practical insights from Cerba Research’s experience supporting early-phase oncology studies. Expect clear explanations of biomarker approaches, real examples from laboratory workflows, and guidance on integrating techniques such as flow cytometry, IHC, and NGS to support decision-making in immuno‑oncology.

Overcoming the Challenges of ADC Trials in Breast and Ovarian Cancer Treatment

Published: May 13, 2026

This article explores the key challenges faced in antibody-drug conjugate (ADC) clinical trials for breast and ovarian cancer. It discusses biological hurdles such as tumor resistance, antigen loss, and tumor heterogeneity, as well as practical issues like biomarker variability and complex pharmacokinetic assessment. The post also highlights how trial design and execution can be affected by these factors across global studies.

Read the full blog

Combining Flow Cytometry, IHC, and NGS in Immuno-oncology: The Essential Trio for Biomarker Assessment Success

Published: November 5, 2025

Dive into how combining flow cytometry, IHC, and NGS delivers a powerful, integrated approach for biomarker assessment in immuno-oncology. This post explains why no single technique is enough — and how the trio provides a fuller picture of the immune response, helping to stratify patients, monitor efficacy, and predict outcomes more reliably.

Read the full blog

How Custom Assays and Biobanking Accelerate Clinical Development: A Unified Framework for Better Outcomes

Published: March 11, 2026

Explore how integrating custom assays with high-quality biobanking practices creates a powerful foundation for generating reliable biomarker data, strengthening protocol design, and advancing precision medicine. This post highlights why precision in assay development, sample integrity, and global execution is essential, and how Cerba Research brings these pieces together to drive faster, more confident clinical decisions.

Read the full blog
mIHC of NK cells phenotyping in NSCLC

Reach out to our experts and discover how we can help you transform your research and advance health